Chapter 5

Severity of pulmonary involvement and $^{18}$F-FDG PET activity in sarcoidosis

RLM Mostard, JA Verschakelen, MJPG van Kroonenburgh, PJ Nelemans, PAHM Wijnen, S Vöö, M Drent

Submitted
Abstract

Background
Assessing inflammatory activity is useful in the management of persistent symptomatic sarcoidosis patients. $^{18}$F-FDG PET (PET) appeared to be a sensitive technique to assess inflammatory activity in sarcoidosis. The aim of this study was to evaluate whether the severity of the pulmonary involvement is associated with PET activity in persistent symptomatic sarcoidosis patients.

Methods
Over a 5-year period, relevant clinical data including laboratory and lung function test results were gathered from the medical records of 95 sarcoidosis patients with persistent disabling symptoms who underwent both a PET and a high-resolution computed tomography (HRCT). HRCT scans were classified using a semi-quantitative scoring system and PET findings as positive or negative, respectively.

Results
PET was positive in 77/95 patients, of whom 56 demonstrated pulmonary PET-positivity. HRCT scores were high (7.1±3.6) in patients with positive pulmonary PET findings (n=56) compared to patients with negative pulmonary PET findings (n=39; 3.0±2.9; p<0.001). The diffusion capacity for carbon monoxide (DLCO) (65±20 % predicted) and the forced vital capacity (FVC) (85±24 % predicted) were low in patients with pulmonary PET-positivity versus those with negative pulmonary PET findings (79±16 % predicted; p=0.001 and 96±22 % predicted; p=0.044, respectively). Interestingly, out of the 26 patients with fibrotic changes, 22 (85%) had positive pulmonary PET findings, of whom 18/22 (82%) showed extrathoracic PET-positive lesions and 16/22 (73%) showed signs of serological inflammation.

Conclusions
The severity of the pulmonary involvement, assessed by HRCT features and lung function parameters, appeared to be associated with increased PET activity in sarcoidosis. The majority of patients with fibrotic changes demonstrated inflammatory activity, next to pulmonary also at extrathoracic sites.
Introduction

Sarcoidosis is a multisystemic disease characterized by activity of cellular immunity with formation of noncaseating granuloma in various organ systems. The majority of deaths from sarcoidosis results from respiratory failure and no universal definition exists for what constitutes ‘active’ pulmonary disease. It is therefore important to accurately assess pulmonary involvement. The reliable detection of changes in pulmonary disease severity in sarcoidosis by using chest radiography and lung function testing has proved problematic. Forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLCO) have been regarded as the most accurate pulmonary function measures of pulmonary involvement in sarcoidosis and deterioration is regarded as an indicator of disease activity in sarcoidosis. However, assessment of disease activity through lung function tests requires evidence of progression between two measurements and so does not reflect the current status. Moreover, lung function testing cannot distinguish between reversible granulomatous lesions and irreversible fibrotic changes, and correlates only modestly with the level of dyspnea reported by patients. Although chest radiography (CXR) is most often the first diagnostic imaging study for assessment of pulmonary involvement in sarcoidosis, the radiographic score (stages 0-IV) possesses limited value in predicting inflammatory activity.

The high-resolution CT (HRCT) uses short scanning times and thin collimation, making it possible to demonstrate lung parenchyma in detail and detect abnormal changes of the lung parenchyma at an early stage. The presence and extent of parenchymal abnormalities on HRCT has been found to correlate with respiratory functional impairment in sarcoidosis. However, HRCT is a morphological imaging technique that provides only indirect information on the underlying metabolic changes. Due to pre-existing major abnormalities, HRCT features are therefore frequently of limited value for the assessment of inflammatory activity in sarcoidosis patients with pulmonary fibrosis, since it is not possible to differentiate between fibrotic and residual granulomatous components in the parenchymal consolidations.

¹⁸F-FDG PET/CT (PET) is used to detect high glucose metabolism and has been shown to be useful for the assessment of inflammatory activity in sarcoidosis. Recently, elevated serological inflammatory markers were found to be associated with PET-positivity. To date, only limited information is available about the relationship between morphological- and functional pulmonary abnormalities, and metabolic changes as measured by PET findings in sarcoidosis patients. The aim of the present study was to evaluate whether the severity of pulmonary involvement as assessed by HRCT features and lung function parameters is associated with PET activity in sarcoidosis.
Materials and methods

We reviewed the medical records of all sarcoidosis patients referred to the interstitial lung disease service (lid care team) of the department of Respiratory Medicine at the Maastricht University Medical Centre (Maastricht, The Netherlands), a tertiary referral center, between June 2005 and September 2010. All sarcoidosis patients who underwent both a PET and a HRCT (n=106) were included. The indication for performing the PET was the presence of unexplained disease related disabling symptoms that persisted for at least one year. Persistent disabling symptoms were defined as the presence of more than one symptom that had substantial influence on quality of life, and that could not be explained with the results of routine investigations, including the absence of lung functional or chest radiographic deterioration. These symptoms included fatigue (Fatigue Assessment Scale [FAS] ≥22),^20^ symptoms compatible with small fiber neuropathy (SFN; SFN Screenings List [SFNSL] score ≥11),^21^ arthralgia and/or muscle pain, dyspnea (MRC dyspnea scale ≥3), exercise intolerance or coughing. Laboratory and lung-function testing were performed within a 2-week interval before or after the HRCT. PET scans were made within a 3-months interval before or after the HRCT, without changing the therapy during this period. In all cases, patients had a clinical presentation compatible with sarcoidosis. The diagnosis was based on consistent clinical features and bronchoalveolar lavage (BAL) fluid analysis results, according to the international guidelines.^1^ The diagnosis was confirmed histological, demonstrating noncaseating epitheloid cell granulomas, in most cases (75%). Patients with known co-morbid conditions associated with PET positive findings were excluded. Therefore, five patients with common variable immunodeficiency (CVID), five patients with malignancy and one patient with both rheumatoid arthritis and amyloidosis were excluded. After exclusion for these criteria, 95 patients were selected. The study protocol was approved by the Medical Research Ethics Committee of our institution.

Laboratory tests

Serum angiotensin-converting enzyme (ACE) was measured by colorimetric method (cat. no. FU 116; Fujirebio Inc.), the reference interval was 9-25 U/l. Serum levels of soluble interleukin-2 receptor (sIL-2R) were analyzed in commercially available Diaclone ELISA kits (Sanquin, Amsterdam, The Netherlands) and considered elevated if >3154 pg/l. Serum levels of neopterin were evaluated by a competitive ELISA (IBL; Hamburg, Germany). Serum levels were considered elevated if >2.5 ng/l. Results for combined serological inflammatory marker testing (ACE, sIL-2R and neopterin) were considered positive if at least one of the serological inflammatory markers was elevated.
C-reactive protein (CRP) was measured using a turbidimetric method performed using the Beckman synchron CX-7 system (kit 465231; Mijdrecht, The Netherlands). The detection limit for CRP was 2 µg/ml, with a normal range of 2-9 µg/ml.

**Chest radiography**

According to the Scadding radiographic staging system, five stages of radiographic abnormality (0-IV) were recognized.1

**Lung function tests**

FVC was measured with a pneumotachograph (Masterlab, Jaeger, Würzburg, Germany). DLCO was measured by the single-breath method (Masterlab, Jaeger, Würzburg, Germany). Values were expressed as a percentage of predicted values.22

**Imaging**

Thin-section scans with 1-mm collimation were obtained at 10-mm intervals through the chest (Somaton Plus, Siemens, Erlangen, Germany). The scanning parameters included 137 kvp, 255 mA, and 1-s scanning time. Both mediastinal (width 400 HU, level 40 HU) and lung (width 1600 HU, level -800 HU) window images were obtained. Scans were reconstructed with a high-frequency reconstruction algorithm.

A whole body 18F-FDG PET/CT scan was performed using a Gemini® PET-CT (Philips Medical Systems) scanner with time-of-flight (TOF) capability, together with a 64-slice Brilliance CT scanner. Patients were fasting for at least six hours before the examination. In all patients blood glucose was measured to ensure that the blood glucose was below 10 mmol/ml. 18F-FDG (GE Health, Eindhoven, The Netherlands) was injected intravenously and followed by physiologic saline (10 ml). The injected total activity of FDG depended on the weight of the patient. Mean injected dose was: 200 MBq. After a resting period of 45 minutes (time needed for uptake of FDG) PET and CT images were acquired from the head to the feet. A low dose CT-scan was performed without intravenous contrast and was used for attenuation correction of the PET images. The PET images were acquired in 5-minute bed positions. The complete PET data set was reconstructed iteratively with a reconstruction increment of 5 mm to provide isotropic voxel.

**Image analysis**

An experienced thoracic radiologist (JV), blinded to the patient’s clinical history and to the PET findings, classified the scans of both lungs using a semiquantitative HRCT scoring system that has been described by Oberstein et al.13 and that has been used in previous studies of our group.6 This scoring system is explained in detail in Table 5.1.
Table 5.1 Definition of abnormal high-resolution computed tomography (HRCT) findings in sarcoidosis, adapted from Oberstein et al.\textsuperscript{13}, visual score.

<table>
<thead>
<tr>
<th>Lung volume affected&lt;sup&gt;a&lt;/sup&gt;</th>
<th>No lesions: 0</th>
<th>&lt;33%:1</th>
<th>&lt;66%:2</th>
<th>&gt;66%:3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical patterns of parenchymal involvement</td>
<td>BVB</td>
<td>PC</td>
<td>ND</td>
<td>LS</td>
</tr>
<tr>
<td>Pathological findings&lt;sup&gt;b&lt;/sup&gt;</td>
<td>None: 0</td>
<td>Minor:1</td>
<td>Moderate: 2</td>
<td>Pronounced:3</td>
</tr>
<tr>
<td>PL</td>
<td>LN</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BVB: thickening or irregularity of the bronchovascular bundle; PC: parenchymal consolidation (including ground-glass opacifications); ND: intraparenchymal nodules; LS: septal and nonseptal lines; PL: focal pleural thickening; LN: enlargement of the mediastinal lymph nodes

The total score is obtained by adding up the individual scores (BVB, ND, LS, PC, LN, and PL)

\textsuperscript{a} The lung volume affected is quantified by a visual score: 0=no lesions found; 1=up to 33%; 2=up to 66%; and 3=more than 66% of the volume affected

\textsuperscript{b} The PL and the enlargement of the LN (with a short axis of 1 cm or more considered enlarged) were quantified: 0=no pathological findings; 1=minor; 2=moderate; and 3=pronounced changes

Separately, the presence of signs of fibrosis (architectural distortion as shown by distortion of the airways and blood vessels, irregular distortion of the septal and intralobular lines, retraction of the hila and fissures, cystic formation and traction bronchiectasis)\textsuperscript{23,24} was evaluated.

All PET were interpreted by an experienced nuclear medicine physician (MvK), blinded to the patient’s clinical history and to the HRCT findings. PET findings in the lungs, lymph nodes, or other soft tissues or bones were scored as either positive or negative. A positive PET-scan interpretation was performed visually, with a threshold standardized uptake value (SUVmax) ≥2.5. \textsuperscript{18}F-FDG uptake was quantified by drawing a region of interest around the area of pathology of the co-registered transaxial slice. SUVmax was calculated as the maximal pixel activity within the region of interest. The degree of increased metabolic activity in the pulmonary parenchyma needed to be higher than the mediastinal background.

In a next step in a consensus meeting between radiologist and nuclear medicine physician, in the patients with pulmonary PET-positivity, the area of most intensive thoracic \textsuperscript{18}F-FDG uptake was identified and the HRCT pattern in this region was assessed. This predominant HRCT substrate of thoracic \textsuperscript{18}F-FDG uptake was classified as one of the items included in the HRCT score. Inter-reader reliability of the total HRCT score and of the simple PET classification system we used proved to be very good, as reported in previous studies with the same observers (weighted kappa 0.99 and 1.00, respectively).\textsuperscript{6,19} Accordingly, in the present study, observation by a single radiologist and a single nuclear physician was regarded to be sufficient.
Statistical procedure

Statistical analyses were performed using SPSS, version 15.0 for Windows. Differences were tested for statistical significance using the Student’s t-test for independent samples in case of continuous variables or chi-square test in case of categorical variables. A p-value of <0.05 (two sided) was considered to indicate statistical significance.

Receiver operating characteristic (ROC) curves were constructed to evaluate the ability of the total HRCT score and the HRCT subscores to predict the presence of PET-positive results. Area under the curve (AUC) values with 95% confidence intervals (CI) were used to quantify and visualise the strength of the association.

Results

In Table 5.2, relevant demographic and clinical characteristics of the studied sarcoidosis patients (87 Caucasians, five of African origin and three of Asian origin) categorized by absence (n=39: 41%) or presence (n=56: 59%) of positive PET findings in the pulmonary parenchyma are summarized. The median SUVmax in the PET-positive patients was 7.0 (2.5-24.2).

Forty patients (71%) in the pulmonary PET-positive group demonstrated one or more extrathoracic lesions. In the pulmonary PET-negative group, 21 patients had extrathoracic positive PET findings. Extrathoracic positive PET findings in the sarcoidosis patients categorized by absence or presence of positive PET findings in the pulmonary parenchyma are shown in Table 5.3.

Relation between morphological and metabolic changes

Association between HRCT (sub)scores and pulmonary PET-positivity

The total HRCT score as well as the subscores of the 56 patients with pulmonary PET-positivity was high compared with the 39 patients with pulmonary PET-negativity (see Table 5.4).

ROC curve results for the association between the total HRCT score and pulmonary PET-positive results are presented in Figure 5.1. The AUC was 0.81 (95% CI: 0.73-0.90). The AUCs of the various HRCT patterns as included in the HRCT score are presented in Table 5.5. All patients with a total HRCT score >9 (n=17) had positive PET findings and all patients with a total HRCT score >10 (n=16) had pulmonary positive PET findings. None of the patients with a total HRCT score of 0 points (n=11) had pulmonary PET-positive findings, nevertheless five of them had extrathoracic positive PET findings and two of them showed increased serological inflammatory markers.
Table 5.2 Demographic and clinical characteristics of the sarcoidosis patients categorized by absence or presence of positive PET findings in the pulmonary parenchyma.

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>Pulmonary parenchyma PET - patients (n=39)</th>
<th>Pulmonary parenchyma PET + patients (n=56)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>44 (22-72)</td>
<td>44 (22-74)</td>
<td>48 (24-76)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>22 (56%)</td>
<td>33 (59%)</td>
<td>NS</td>
</tr>
<tr>
<td>Time since diagnosis (yrs)</td>
<td>2 (1-20)</td>
<td>2 (1-21)</td>
<td>NS</td>
</tr>
<tr>
<td>Therapy total number (%)</td>
<td>9 (23%)</td>
<td>17 (30%)</td>
<td>NS</td>
</tr>
<tr>
<td>1/2/3/4</td>
<td>4/1/4/0</td>
<td>9/6/1/1</td>
<td>NS</td>
</tr>
<tr>
<td>ACE (9-25 U/l)</td>
<td>15 (1-35)</td>
<td>19 (3-60)</td>
<td>0.030</td>
</tr>
<tr>
<td>sIL-2R (240-3154 pg/ml)</td>
<td>2028 (518-9662)</td>
<td>3451 (1191-15000)</td>
<td>0.004</td>
</tr>
<tr>
<td>Neopterin (&lt;2.5 ng/ml)</td>
<td>1.7 (0.8-2.8)</td>
<td>3.0 (0.7-18.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>CRP (2-9 µg/ml)</td>
<td>4 (1-80)</td>
<td>6 (1-70)</td>
<td>NS</td>
</tr>
<tr>
<td>CXR stage II</td>
<td>22/7</td>
<td>8/9</td>
<td>0.016</td>
</tr>
<tr>
<td>CXR stage I/II/IV</td>
<td>2/5/3</td>
<td>11/5/23</td>
<td>NS</td>
</tr>
<tr>
<td>FVC total (% pred)</td>
<td>96±22</td>
<td>85±24</td>
<td>0.044</td>
</tr>
<tr>
<td>CXR 0-I</td>
<td>98±22</td>
<td>105±11</td>
<td>NS</td>
</tr>
<tr>
<td>CXR II-IV</td>
<td>91±24</td>
<td>80±20</td>
<td>NS</td>
</tr>
<tr>
<td>DLCO total (% pred)</td>
<td>79±16</td>
<td>65±20</td>
<td>0.001</td>
</tr>
<tr>
<td>CXR 0-I</td>
<td>81±16</td>
<td>76±19</td>
<td>NS</td>
</tr>
<tr>
<td>CXR II-IV</td>
<td>71±16</td>
<td>60±19</td>
<td>NS</td>
</tr>
<tr>
<td>RFI total</td>
<td>21/39 (54%)</td>
<td>45/56 (81%)</td>
<td>0.008</td>
</tr>
<tr>
<td>CXR 0-I</td>
<td>14/29 (48%)</td>
<td>11/17 (65%)</td>
<td>NS</td>
</tr>
<tr>
<td>CXR II-IV</td>
<td>7/10 (70%)</td>
<td>34/39 (87%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data are presented as median with range in parentheses; mean±SD; absolute numbers or percentages if appropriate. PET: positron emission tomography; -: negative; +: positive; n: number; yrs: years; NS: not significant; therapy total: total number of patients treated at time of PET scanning; 1: prednisone monotherapy; 2: methotrexate monotherapy; 3: prednisone and methotrexate combination therapy; 4: methotrexate and infliximab combination therapy; ACE: serum angiotensin-converting enzyme; sIL-2R: soluble interleukin-2 Receptor; CRP: C-reactive protein; CXR: chest X-ray; FVC: forced vital capacity; % pred: percentage of predicted values; DLCO: diffusion capacity for carbon monoxide; RFI: respiratory functional impairment, defined as present if DLCO was <80%, FEV1 was <80%, or FVC was <80% of the predicted value. p<0.05 was considered to indicate significance.

Table 5.3 Extrathoracic and mediastinal positive PET findings in the sarcoidosis patients categorized by absence or presence of positive PET findings in the pulmonary parenchyma.

<table>
<thead>
<tr>
<th>Extrathoracic and mediastinal positive PET findings</th>
<th>Pulmonary parenchyma PET - patients (n=39; CXR 0-I/II-IV: 29/10)</th>
<th>Pulmonary parenchyma PET + patients (n=56; CXR 0-I/II-IV: 17/39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mediastinal lymph nodes</td>
<td>15 (39%)</td>
<td>43 (77%)</td>
</tr>
<tr>
<td>Peripheral lymph nodes</td>
<td>18 (46%)</td>
<td>38 (68%)</td>
</tr>
<tr>
<td>Liver</td>
<td>0</td>
<td>9 (16%)</td>
</tr>
<tr>
<td>Spleen</td>
<td>2 (5%)</td>
<td>14 (25%)</td>
</tr>
<tr>
<td>Parotid glands</td>
<td>4 (10%)</td>
<td>13 (23%)</td>
</tr>
<tr>
<td>Skin</td>
<td>1 (3%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Bone</td>
<td>7 (18%)</td>
<td>16 (29%)</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
</tbody>
</table>

Data are presented as absolute numbers with percentages in parentheses; PET: positron emission tomography; n: number; CXR: chest X-ray
Table 5.4  HRCT features of the sarcoidosis patients categorized by absence or presence of positive PET findings in the pulmonary parenchyma.

<table>
<thead>
<tr>
<th></th>
<th>Pulmonary parenchyma PET - patients (n=39)</th>
<th>Pulmonary parenchyma PET + patients (n=56)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total HRCT score</td>
<td>3.0±2.9</td>
<td>7.1±3.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BVB score</td>
<td>0.4±0.7</td>
<td>1.3±1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ND score</td>
<td>0.6±0.7</td>
<td>1.3±0.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LS score</td>
<td>0.3±0.5</td>
<td>0.8±0.8</td>
<td>0.001</td>
</tr>
<tr>
<td>PC score</td>
<td>0.4±0.6</td>
<td>1.0±0.8</td>
<td>0.001</td>
</tr>
<tr>
<td>PL score</td>
<td>0.5±0.8</td>
<td>1.3±1.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LN score</td>
<td>0.8±1.1</td>
<td>1.5±0.9</td>
<td>0.002</td>
</tr>
<tr>
<td>Fibrosis on HRCT</td>
<td>4 (10%)</td>
<td>22 (39%)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD; absolute numbers or percentages if appropriate. PET: positron emission tomography; -: negative; +: positive; n: number; HRCT: high-resolution computed tomography; BVB: thickening or irregularity of the bronchovascular bundle; PC: parenchymal consolidation (including ground-glass opacifications); ND: intraparenchymal nodules; LS: septal and nonseptal lines; PL: focal pleural thickening; LN: enlargement of the mediastinal lymph nodes. p<0.05 was considered to indicate significance.

Table 5.5  Area under the curve (AUC) values for the association between positive pulmonary parenchymal results and the different HRCT patterns as included in the HRCT score.

<table>
<thead>
<tr>
<th></th>
<th>AUC</th>
<th>Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>BVB</td>
<td>0.75</td>
<td>0.65-0.85</td>
</tr>
<tr>
<td>ND</td>
<td>0.72</td>
<td>0.61-0.82</td>
</tr>
<tr>
<td>LS</td>
<td>0.68</td>
<td>0.58-0.79</td>
</tr>
<tr>
<td>PC</td>
<td>0.75</td>
<td>0.58-0.80</td>
</tr>
<tr>
<td>PL</td>
<td>0.68</td>
<td>0.65-0.85</td>
</tr>
<tr>
<td>LN</td>
<td>0.81</td>
<td>0.57-0.80</td>
</tr>
</tbody>
</table>

AUC: area under the curve; HRCT: high-resolution computed tomography; BVB: thickening or irregularity of the bronchovascular bundle; PC: parenchymal consolidation (including ground-glass opacifications); ND: intraparenchymal nodules; LS: septal and nonseptal lines; PL: focal pleural thickening; LN: enlargement of the mediastinal lymph nodes.

Figure 5.1  Receiver operating characteristic (ROC) curve of the association between the total HRCT score and positive PET results. AUC 0.81; CI 0.73-0.90
**Predominant HRCT pattern on area of most intensive thoracic $^{18}$F-FDG uptake**

The predominant HRCT pattern on the area of most intensive thoracic $^{18}$F-FDG uptake were parenchymal consolidations in 48%, lymph nodes in 25%, intraparenchymal nodules in 21%, septal and non-septal lines in 4% and pleural thickening in 2% of the patients, respectively.

**Presence of fibrosis on HRCT**

Signs of fibrosis on HRCT were present in 26 patients. The majority (22/26; 85%) of these patients showed positive pulmonary PET findings. Median SUVmax in these patients was 7.1 (3.1-16.2). Extrathoracic PET-positive findings were present in 18 (82%) and positive combined serological inflammatory marker testing in 16 (73%), respectively. An example of pulmonary PET-positivity in a sarcoidosis patient with fibrotic changes on HRCT is shown in Figure 5.2.

![Figure 5.2](image)

*Figure 5.2* Example of pulmonary PET-positivity in a 45-year-old female sarcoidosis patient with fibrotic changes on HRCT.

The transversal PET/CT fusion image at thoracic level (upper image) shows areas of FDG accumulation bilateral in the hilar regions and in several mediastinal lymph nodes. The HRCT image (lower image) at the same level shows architectural parenchymal distortion with parenchymal opacities, thickening and irregularity of the bronchovascular bundle, irregular pleural thickening and in the left lung a limited area of honeycombing.
Relation between functional tests and metabolic changes

Association between lung function and pulmonary PET-positivity

In the PET-positive patient group, DLCO was lower in patients with pulmonary PET-positivity (65±20 % predicted) versus the patients with exclusively extrapulmonary PET-positivity (79±16 % predicted; p=0.001). The predictive value for PET-positivity of a model based on lung function parameters expressed by the AUC was for FVC and DLCO 0.62 (CI 0.49-0.74) and 0.73 (CI 0.60-0.83), respectively. All patients with DLCO<45% (n=8) or FVC<50% (n=3) showed positive pulmonary PET findings.

Discussion

In this study, we demonstrated that the severity of pulmonary involvement as assessed by HRCT features and lung function parameters is associated with pulmonary PET activity in sarcoidosis. Remarkably, inflammatory activity appeared to be present in the majority of patients with signs of fibrosis on HRCT.

HRCT features and PET findings

All HRCT features included in the used HRCT scoring system were associated with pulmonary PET positivity. Previous follow-up CT studies in patients with pulmonary sarcoidosis have shown that nodular opacities represent potentially reversible findings, and thus the presence of inflammatory activity in these nodules could be expected. However, the use of HRCT findings to identify the presence of residual active, reversible lesions in a background of fibrosis is much more difficult. The previously mentioned follow-up CT scan studies showed that cystic air spaces and architectural distortion are irreversible findings, with or without treatment. Based on the results of the present study, these latter findings do not exclude the presence of associated potentially reversible pulmonary parenchymal lesions, though. The used HRCT scoring system was criticized in the past because of the lack of an included fibrosis score. Therefore, in the present study the presence of signs of fibrosis on HRCT was scored separately. The majority of patients with signs of fibrosis on HRCT and CXR had positive pulmonary PET findings. Increased FDG uptake has also been observed in patients with idiopathic pulmonary fibrosis (IPF). All of the models proposed for the pathogenesis of pulmonary fibrosis involve a central role for fibroblasts, which are known to express glucose transporter-1. It is tempting to speculate that the elevated FDG uptake in patients with fibrotic changes, including honeycombing, might be a reflection of increased fibroblast metabolism and not due to inflammatory activity sensu strictu. In contrast to IPF patients, the majority of the pulmonary PET-positive sarcoidosis patients with fibrosis on HRCT in our population showed extrathoracic PET-positive findings (82%) and increased serological
inflammatory markers (73%). Furthermore, mean SUVmax (7.1±3.6) in these patients was higher than reported by two studies with IPF patients 26,27 (0.99 ± 0.29 and 2.9±1.1, respectively). These findings strongly suggest that PET-positive findings in sarcoidosis patients with CXR stage IV are indeed related to inflammatory activity.

Deciding which sarcoidosis patients with pulmonary fibrosis may benefit from pharmacological treatment remains a challenge to clinicians, as it is not always clear whether respiratory symptoms in these patients are a result of organ damage or due to ongoing inflammation or both. Careful consideration also needs to be given to the likely benefits of any therapy, set against the risk of adverse events, since adding the burden of medication like corticosteroids to these disabled patients might harm them even further. To date, there is no medication with the capability of reversing fibrosis, but there is hope that treatment can arrest fibrosis of reversible granulomas that persist among the fibrotic elements.31 This is in line with the results of the post-hoc analysis in the Sarcoidosis Investigators study, which suggested a greater benefit of infliximab therapy in patients with more severe disease, including radiographic stage IV.32 Techniques that are purported to differentiate fibrotic tissue from granulomatous tissue with inflammatory activity are therefore of importance. There is little evidence to support corticosteroid or immunosuppressive treatment of fibrotic lung disease unless the presence of inflammatory activity can be demonstrated.31 Several reports have demonstrated a significant reduction of FDG uptake after the initiation or modification of treatment in sarcoidosis patients.16,18,33-35 Keijzers et al.33 demonstrated that changes in PET-imaging in a small cohort of sarcoidosis patients treated with infliximab considerably correlated with clinical signs of improvement. Another study showed that diffuse pulmonary parenchymal activity in sarcoidosis patients, as imaged by 18F-FDG PET, predicted a future deterioration of DLCO when medical treatment was withheld, while treatment with corticosteroids or immunosuppressive drugs significantly improved lung function.36 Teirstein et al.18 described that the improvement of symptoms, conventional imaging findings, and physiological data paralleled the therapy-related decrease in SUVmax as seen on the PET scans in most patients, including three patients with radiographic stage IV. Although the exact importance of the presence of inflammatory activity for treatment decisions obviously needs to be established in future prospective, longitudinal studies, the above-mentioned findings support the clinical and therapeutic relevance of positive PET findings in sarcoidosis. Moreover, the detection of PET-positive extrathoracic lesions can be helpful to differentiate between sarcoidosis and other ILD like IPF in patients presenting with pulmonary fibrosis.

HRCT appeared to be superior to CXR for presuming positive pulmonary PET findings because pulmonary PET-positivity was assessed or excluded with specific values of the total HRCT score (in case of respectively >10 and 0 points). A positive relation was found between pulmonary positive PET findings and higher CXR stages, however, CXR stage 0 did not exclude positive pulmonary PET findings (27% had positive pulmonary PET findings) and a minority of patients (12%) with CXR stage IV had negative
pulmonary PET findings. It should be noted that although all patients with a total HRCT score of 0 points (n=11) had negative pulmonary PET findings, five of them demonstrated extrathoracic positive PET findings. This warrants the use of other diagnostic tools like PET for assessment of inflammatory activity in patients with persistent disabling symptoms in the absence of lung functional deterioration or serological signs of inflammatory activity and with no or limited (total HRCT score<10) radiologic abnormalities.

Lung function and PET findings

The relationship between respiratory functional impairment and morphological abnormalities on HRCT is well established in sarcoidosis patients.6,12,23,37 The present study demonstrated a relationship between decreased lung function and pulmonary PET-positivity. This is in accordance with the above-mentioned study of Keijzers et al.36 and with a study in a population of patients with mixed interstitial lung disease.27 In the present study, PET-positivity was demonstrated in all patients with a DLCO<45% or FVC<50%. Further studies are required to prove whereas these values can be adopted as threshold for clinical use.

This study has several limitations. First, the study population was gathered in a referral centre for sarcoidosis, so the refractory character of the disease may have been more severe than in a general sarcoidosis population. Follow-up of the patients was generally performed by their own physicians and therefore no standardized follow-up data were available for analysis. Second, HRCT and PET were not performed in every referred patient, since only part of the patients was referred because of unexplained persistent disease related symptoms. This might cause a selection bias. The questions asked by the referring physicians and the reasons for referring the patients to our centre were very diverse and these investigations were not necessary in all patients to answer the questions appropriately. However, this does not mean that these patients had less severe sarcoidosis.

In conclusion, the severity of pulmonary involvement as assessed by HRCT features and lung function parameters was associated with increased PET activity in sarcoidosis. Interestingly, inflammatory activity was demonstrated by positive PET findings, next to pulmonary also extrathoracic (82%), as well as by serological signs of inflammatory activity (73%) in the majority (85%) of patients with radiological fibrotic changes.
References


